$102.98
0.060.06%
Last update: Nov 10, 7:49 PM
Halozyme Therapeutics Inc
HALONASDAQ
Halozyme Therapeutics rose 46.8% from $70.13 to $102.92, ahead of the S&P 500's +9.8%. Its worst day was Nov 6 (−15.7%), and its low came Mar 27 at $61.63.
Nov 11, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Halozyme Therapeutics shares fell 9.4%, while the S&P 500 rose 0.1%.
−9.4% · S&P 500 +0.1%
EPS of $-0.24 missed the $2.15 estimate on $451.8M revenue (est. $447.1M); FY revenue guidance of $1.7B–$1.8B against the $1.6B consensus.
Story events cover the past 12 months · Times ET
−9.0% · S&P 500 +0.5%
Halozyme Therapeutics closed at its lowest level of the year, 12.1% below where the year started.
−2.6% · S&P 500 −1.7%
EPS of $1.60 beat the $1.51 estimate on $376.7M revenue (est. $358.8M); FY revenue guidance of $1.7B–$1.8B against the $1.8B consensus.
+6.8% · S&P 500 −0.2%
EPS of $2.28 beat the $1.80 estimate on $481.0M revenue (est. $405.2M); FY revenue guidance of $1.8B–$1.9B against the $1.8B consensus.
+20.2%, the year's best day · S&P 500 +0.6%
Halozyme Therapeutics closed at its highest level of the year, 87.1% above where the year started.
+0.9% · S&P 500 −0.4%
EPS of $2.39 beat the $2.32 estimate on $493.0M revenue (est. $489.4M); FY revenue guidance of $1.9B–$1.9B against the $1.9B consensus.
−15.7%, the year's worst day · S&P 500 +0.3%
Where it ended: a close of $102.92 on Nov 9, 2026. Up next: Q4 2026 earnings on Feb 16, 2027 (EPS est. $2.61, revenue est. $550.9M).
Nothing in the past 12 months.
All HALO dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for HALO and SPY from Benzinga historical bars. Not investment advice.
